<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371967</url>
  </required_header>
  <id_info>
    <org_study_id>ML29507</org_study_id>
    <nct_id>NCT02371967</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)</brief_title>
  <acronym>ROSETT</acronym>
  <official_title>A Prospective Observational Study of Erivedge® Treatment, Effectiveness, and Safety Outcomes in Patients With Advanced Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This prospective, observational, cohort study is designed to assess the effectiveness and
      safety outcomes of vismodegib and to assess actual day-to-day disease and participant
      management by the physician.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 8, 2015</start_date>
  <completion_date type="Anticipated">December 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 19, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Clinical Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)</measure>
    <time_frame>From the date of first treatment up to the date of progression or death from any cause (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Clinical Response as Assessed by Investigator According to RECIST v1.1</measure>
    <time_frame>From the date of first treatment until the date of first documented confirmed complete response (CR) or partial response (PR) (whichever occurs first) (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Clinical Response as Assessed by Investigator According to RECIST v1.1</measure>
    <time_frame>From the date of occurrence of first clinical response up to the date of progression or death from any cause (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Experience a Recurrence</measure>
    <time_frame>From Baseline up to end of study (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) as Assessed by Investigator According to RECIST v1.1</measure>
    <time_frame>From the date of first treatment up to the date of progression or death from any cause (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of first treatment until death due to any cause (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From Baseline up to end of study (up to approximately 3 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Vismodegib Treatment</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Vismodegib Treatment Interruption</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>No Gorlin Syndrome Participants With No Prior HPI Exposure</arm_group_label>
    <description>BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Gorlin Syndrome Participants With Prior HPI Exposure</arm_group_label>
    <description>BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gorlin Syndrome Participants With/Without Prior HPI Exposure</arm_group_label>
    <description>BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.</description>
    <arm_group_label>No Gorlin Syndrome Participants With No Prior HPI Exposure</arm_group_label>
    <arm_group_label>No Gorlin Syndrome Participants With Prior HPI Exposure</arm_group_label>
    <arm_group_label>Gorlin Syndrome Participants With/Without Prior HPI Exposure</arm_group_label>
    <other_name>Erivedge®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include adult participants with advanced BCC, in whom the
        treating physician has made the decision to commence vismodegib treatment (in accordance
        with the local label).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BCC that meets one of the study's pre-specified cohort definitions

          -  Physician's decision to treat participant with vismodegib as per local label

          -  Participant who has not participated in a clinical trial within 90 days prior to study
             enrollment, with the exception of participants who meet the criteria for Cohort 2 (No
             Gorlin Syndrome Participants With Prior HPI Exposure)

        Exclusion Criteria:

          -  Female participants are excluded if they are pregnant or if they plan to become
             pregnant during treatment or within 2 years after end of treatment

          -  Male participants with female partners of childbearing potential are excluded if they
             plan to impregnate their partner during treatment or within 2 months after end of
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SU/Sahlgrenska, Hudkliniken</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus; Hudkliniken</name>
      <address>
        <city>Lund</city>
        <zip>222 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiumhemmet</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands universitetssjukhus; Onkologkliniken</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

